Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Thursday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $0.40 on Thursday. The firm’s 50 day moving average price is $0.59 and its 200-day moving average price is $0.50. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.85. The stock has a market cap of $5.84 million, a P/E ratio of -0.26 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. As a group, equities analysts expect that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AEMD. Renaissance Technologies LLC bought a new stake in Aethlon Medical in the fourth quarter worth $25,000. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Aethlon Medical in the 4th quarter worth $26,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical in the 4th quarter worth about $31,000. Virtu Financial LLC purchased a new stake in shares of Aethlon Medical during the 4th quarter valued at about $81,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Aethlon Medical in the 4th quarter valued at about $186,000. 1.99% of the stock is currently owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.